180 related articles for article (PubMed ID: 19378425)
21. Diagnosis of malignant pericarditis: a single centre experience.
Pawlak Cieślik A; Szturmowicz M; Fijałkowska A; Gątarek J; Gralec R; Błasińska-Przerwa K; Szczepulska-Wójcik E; Skoczylas A; Bilska A; Tomkowski W
Kardiol Pol; 2012; 70(11):1147-53. PubMed ID: 23180523
[TBL] [Abstract][Full Text] [Related]
22. A fuzzy-classifier using a marker panel for the detection of lung cancers in asbestosis patients.
Schneider J; Bitterlich N; Kotschy-Lang N; Raab W; Woitowitz HJ
Anticancer Res; 2007; 27(4A):1869-77. PubMed ID: 17649786
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of diagnostic value of four tumor markers in bronchoalveolar lavage fluid of peripheral lung cancer.
Li J; Chen P; Mao CM; Tang XP; Zhu LR
Asia Pac J Clin Oncol; 2014 Jun; 10(2):141-8. PubMed ID: 23551358
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer.
Okamura K; Takayama K; Izumi M; Harada T; Furuyama K; Nakanishi Y
Lung Cancer; 2013 Apr; 80(1):45-9. PubMed ID: 23352032
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
26. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
27. Cut-off-independent tumour marker evaluation using ROC approximation.
Bitterlich N; Schneider J
Anticancer Res; 2007; 27(6C):4305-10. PubMed ID: 18214036
[TBL] [Abstract][Full Text] [Related]
28. [Tumor markers in lung cancer].
Niho S; Shinkai T
Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
[TBL] [Abstract][Full Text] [Related]
29. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Beinert T; Fürst H; Fink U
Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
[TBL] [Abstract][Full Text] [Related]
30. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
31. Multiple tumour markers for diagnosis, management and follow-up of potentially resectable lung cancer.
Ratto GB; Mereu C; Rovida S
Panminerva Med; 1993 Dec; 35(4):186-92. PubMed ID: 8202329
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of a multiple biomarker assay in bronchoalveolar lavage (BAL) and serum for the diagnosis of small cell lung cancer.
Nikliński J; Chyczewska E; Furman M; Kowal E; Laudanski J; Chyczewski L
Neoplasma; 1993; 40(5):305-8. PubMed ID: 8272160
[TBL] [Abstract][Full Text] [Related]
33. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
Ebert W; Hoppe M; Muley T; Drings P
Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
[TBL] [Abstract][Full Text] [Related]
34. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
[TBL] [Abstract][Full Text] [Related]
35. [Clinical significance of tumor markers CYFRA 21-1 and neuron-specific enolase in lung cancer].
Kushlinskiĭ NE; Liubimova NV; Lemeshko AO; Vasil'ev AV; Davydov MI
Biull Eksp Biol Med; 1997 Jan; 123(1):98-100. PubMed ID: 9213472
[No Abstract] [Full Text] [Related]
36. Diagnostic value of chest radiography, computed tomography and tumour markers in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Seemann O; Dienemann H; Schalhorn A; Prime G; Fink U
Eur J Med Res; 1999 Aug; 4(8):313-27. PubMed ID: 10471543
[TBL] [Abstract][Full Text] [Related]
37. Performance characteristics of an automated assay for the quantitation of CYFRA 21-1 in human serum.
Patel JL; Erickson JA; Roberts WL; Grenache DG
Clin Biochem; 2010 Dec; 43(18):1449-52. PubMed ID: 20875814
[TBL] [Abstract][Full Text] [Related]
38. [Interpretation of tumor markers in pulmonary tuberculosis].
Racil H; Saad S; Cheikh Rouhou S; Chaouch N; Zarrouk M; Yaalaoui S; Chabbou A
Rev Pneumol Clin; 2009 Apr; 65(2):127-8. PubMed ID: 19375055
[No Abstract] [Full Text] [Related]
39. Comparative studies of CAM 123-6 and carcinoembryonic antigen for the serological detection of pulmonary adenocarcinoma.
Kohno N; Hirasawa Y; Kondo K; Fujioka S; Fujino S; Abe M; Yokoyama A; Hiwada K; Watanabe K; Nishimura J
Cancer Detect Prev; 1997; 21(2):124-8. PubMed ID: 9101072
[TBL] [Abstract][Full Text] [Related]
40. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
